Feedback
Settings

Settings

Goto Application

6,105 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(USVMJSALORZVDV-SDBHATRESA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 611
1.20250353854FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN
US - 20.11.2025
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No 18871252 Applicant Biomea Fusion, Inc. Inventor James T. PALMER

Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds described herein. Methods of using the menin or menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin or menin-MLL interaction.

2.20250352655THERAPEUTIC ANNEXIN-DRUG CONJUGATES AND METHODS OF USE
US - 20.11.2025
Int.Class A61K 47/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
 Appl.No 19282461 Applicant The Board of Regents of the University of Oklahoma Inventor Roger G. Harrison

Therapeutic protein-drug conjugates comprising annexins conjugated to drug payloads for targeting stressed human cells (e.g., cancer cells), bacterial cells, fungal cells, or parasitic cells which express phosphatidylserine. The protein-drug conjugates generally contain multiple drug molecules per annexin molecule. The annexin binds to the surface of cells, but is also endocytosed efficiently, thereby delivering the drug to the cytoplasm of the target cell.

3.20250352490P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF
US - 20.11.2025
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19287868 Applicant Ramot at Tel-Aviv University Ltd. Inventor Ronit SATCHI-FAINARO

Particles made of a polymeric matrix having associated therewith a therapeutically active agent usable in treating a medical condition associated with an overexpression of P-selectin in a subject in need thereof and featuring a P-selectin selective targeting moiety represented by Formula I as defined and described in the specification and claims, compositions comprises these particles and uses thereof, are provided.

4.WO/2025/240781MODIFIED ANTIBODIES AND IMMUNOGLOBULIN FORMATS
WO - 20.11.2025
Int.Class C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
 Appl.No PCT/US2025/029625 Applicant WEREWOLF THERAPEUTICS, INC. Inventor CAFARELLI, Tiziana
Provided herein are modified antibodies or antibody binding fragments thereof that have inhibited binding activity for their cognate antigens. The antibodies or antibody binding fragments comprise an antigen binding domain and two or more blocking elements that are operably linked through a cleavable linker to the antigen binding domain.
5.WO/2025/240412METHODS FOR THE TREATMENT OF CANCER
WO - 20.11.2025
Int.Class A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
 Appl.No PCT/US2025/029054 Applicant DUKE UNIVERSITY Inventor THIELE, Dennis, J.
Methods for treating cancer in a subject in need thereof by administration of a compound of Formula (I) are described herein. The methods may treat cancer by degrading heat shock factor 1 (HSF1), arresting tumor growth, treatment of malignant bone marrow, the selective killing of malignant bone marrow, etc.
6.20250353924ANTI-CD84 ANTIBODIES AND USES THEREOF
US - 20.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No 18866493 Applicant CITY OF HOPE Inventor John C. WILLIAMS

Provided herein are, inter alia, antibodies (e.g. humanized antibodies, chimeric antibodies, monoclonal antibodies, antibody fragments (e.g. scFvs)), which bind Cluster of Differentiation 84 (CD84) with high efficiency and specificity. The antibodies provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for treating cancer and other CD84-related diseases.

7.WO/2025/240416COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
WO - 20.11.2025
Int.Class C07C 275/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
275Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups
28having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
 Appl.No PCT/US2025/029061 Applicant DUKE UNIVERSITY Inventor THIELE, Dennis J.
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
8.WO/2025/235952HUMANIZED ANTI-CD84 ANTIBODIES
WO - 13.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/028746 Applicant CITY OF HOPE Inventor WILLIAMS, John C.
Provided herein are, inter alia, humanized antibodies which bind Cluster of Differentiation 84 (CD84) with high efficiency and specificity. The humanized antibodies provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for treating cancer and other CD84-related diseases.
9.WO/2025/235527CRYSTALLINE FORMS OF A PPAR ALPHA ANTAGONIST
WO - 13.11.2025
Int.Class C07D 249/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
249Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
02not condensed with other rings
081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
10with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
12Oxygen or sulfur atoms
 Appl.No PCT/US2025/028011 Applicant TEMPEST THERAPEUTICS, INC. Inventor JOHNSON, Henry William Beecroft
Described herein are crystalline forms of a compound that is a PPARα antagonist, methods of making such crystalline forms, pharmaceutical compositions and medicaments comprising such crystalline forms, and methods of using such crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of PPARα activity.
10.20250346634CYCLIC PEPTIDES FOR TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR AND MUTATIONS THEREOF FOR DRUG DELIVERY
US - 13.11.2025
Int.Class C07K 7/64
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
64Cyclic peptides containing only normal peptide links
 Appl.No 18868749 Applicant Ariel Scientific Innovations Ltd. Inventor Bat Chen Revital LUBIN

Provided herein is a family of cyclic peptides that exhibit specific affinity to EGFR expressing cells, and that can be used as drug delivery vehicle for labeling agents and cytotoxic drugs against said cells in the context of a peptide-drug conjugates, as well as pharmaceutical compositions including the same, and uses thereof for treating cancer.

# -